Heron Therapeutics

Heron Therapeutics

Heron Therapeutics was founded in 2013, rebranding from its predecessor A.P. Pharma, with Craig Collard stepping in as CEO to reposition the company around acute care and oncology supportive care products. The firm operates as a publicly traded biopharmaceutical company based in San Diego, commercializing its own pipeline rather than managing external capital as a fund or family office would. The company's strategy centers on developing and commercializing treatments for chemotherapy-induced nausea and vomiting (CINV) and post-operative pain management. Its flagship product, SUSTOL (granisetron extended-release injection), is a 5-HT3 receptor antagonist approved for CINV prevention. A second commercial product, CINVANTI (aprepitant injectable emulsion), is a substance P/neurokinin-1 receptor antagonist used in combination with other antiemetics to prevent both acute and delayed CINV. The company later launched APONVIE (HTX-019), a novel formulation of aprepitant for post-operative nausea and vomiting. Its most advanced pipeline candidate, HTX-011 (also known as ZYNRELEF), is a non-opioid dual-acting local anesthetic combining bupivacaine and meloxicam, developed in collaboration with Pacira BioSciences for post-operative pain management. Geographically, the company's commercial footprint is concentrated in the United States, with distribution through specialty pharmacies and wholesalers. As a publicly listed entity on Nasdaq under the ticker HRTX, Heron has raised capital through equity offerings, including a $200 million public offering in 2019 (per SEC filings). In 2022, the company closed a $50 million senior secured term loan facility, and in 2023 it underwent a restructuring to reduce operating costs and extend its cash runway. The company's intellectual property portfolio spans multiple patents covering the SUSTOL and CINVANTI formulations. Recent activity includes a May 2023 debt exchange transaction and a $20 million registered direct offering in February 2024. Structurally, Heron holds a dual identity: it is a Nasdaq-listed pharmaceutical company with no family-office roots, no external capital deployment function, and no investment management mandate. Its business is drug development, FDA approval, and hospital-based commercialization — placing it outside any family office, asset manager, or allocator peer set. The company's capital allocation is purely operational, funding clinical trials and commercial launches rather than deploying capital into external investments or portfolio companies.